Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're talking all penny world stuff. Which is polar opposite of where the company claimed it was headed >>> NASDAQ. You're even throwing Kulwant Malhi (Cannabix's King Clown) into the equation as the supposed guy for financing, flipping and directing Doc Williams (the midnight reader). I mean that's all the old hits from 2018 you're expecting to be the case moving forward (but actually ass backwards). Who the hell wants to go back down that road? What's certain is I won't be someone here to continue ranting about any of those losers. As far as hanging your hat on the psych angle look around. Thus far the top contenders have shaved in excess of 50% off their Market Cap in the last month or so. If Wall Street is devaluing the psych sector, who thinks Algernon has a chance with it's pie in the sky one trick pony for strokes? It's the most extreme angle of any biotech out there chasing psych treatments. It makes for a good story (as long as Moreau isn't the one telling it) but not dollars and cents/sense. As I've said umpteen thousand times well before the split and long trail of Moreau's Drama Queen antics is the Chronic Cough angle is the only thing in the pipeline that has any chance at shareholders recouping loses. Wall Street has rejected all that BS Moreau brought to the table. Hence, back to the pennyland Abyss with an offering that doesn't even have a dollar amount attached to it. Anyone think it odd how the stock dropped a US dollar the following day and another 20% thereafter? They are orchestrating another massive dilution scheme where USA shareholders are locked out. The CADS are at it again. Go to CEO.CA and there's an insider who goes by the name sheepandpigs or whatever. Within his ranting posts he revealed Algernon was onto a "deal" that was not related to NASDAQ. My best guess is they had this planned all along. Why would you go to Wall Street and explicitly tell would be investors they could buy units where the warrants would never trade? Then you turn around and open the floodgates for warrants to trade on the CSE? They are running a massive underhanded dilution scheme and knew this latest news dump would punish the stock to the point of issuing even more shares than last filed with the SEC. F*** Moreau and the entire lot of them.
Burn In Hell
Thanks for the dialog. It beats trying to blame me for all the BS happening with the stock price. If one can't see how they are destroying any value of Algernon one needs their head examined by a board certified physician.
M$
What does your link mean...
D E $ P E R A D O ?
M$
Following the math and common sense regarding pending clinical trials tells a story of doom and gloom on it's own accord. Going from a $5 offering to a $4 offering now likely a $3 offering with matching warrants is not positive by any stretch of the imagination. The math says you are losing your ass while stuck in the mud waiting for any movement on clinical trials or receiving a data readout in advance of raising more money. That too says they have no confidence in the long awaited IPF/CC data readout moving the needle upward. Otherwise why maximize dilution beforehand? The only website out there still trying to blow rainbows and unicorns out to the masses is ceo.ca. It's there you'll find mostly biopub members, fam and friends, bloggers wanting to pump for a quick flip. They have recently calmed down the rhetoric there as they too can see the rainbows and unicorns story falling apart. The NASDAQ uplist appears to remain in peril. It would appear trying to raise money in the USA was a bust. How's that sit with thinking an uplist will have the stock takeoff? Algernon is setting itself up to simply continue trading and fire sale raising capital in pennyland as it did before the crazy ass reverse split of 100 to 1. Again, simple math says a return of investment is slipping further and further away. Phase 1 studies will only increase the dilution. They will be back at the public begging for more money by this time next year. The Chronic Cough angle was their best chance at keeping the company from falling into the pit of hell and they royally blew it. Another Phase 2 study for Chronic Cough isn't even on the calendar to start again and it too would require massive dilution because the current capital raise doesn't account for such expenses. Simple simple simple math and common sense. I've read another's beliefs about where we are in the process the many times it's been posted here. It doesn't address the actual issues happening before our eyes. It's generalizations about some process believed yet to happen for whatever reasons. IMO, it's very confusing to say the least. Doom & Gloom...yeah what else to the story have I missed? I'd love to read others original thoughts.
“Always tell the truth. That way you don’t have to remember what you said” – Mark Twain
“The truth is heavy, therefore few care to carry it” – Unknown
Have @ It
M$
P.S. Once this latest Drama Queen circus act orchestrated by Christopher Moreau (who else?) blows through town, expect the stock to trade around $1 USD.
P.S.S. The good news for those who want to read posts filled with rainbows and unicorns is you'll get the last of my ass once the Top line Data is finally released. I'm no longer waiting for an uplist to Nasdaq having assumed it would potentially be a positive catalyst. It's a wrap on that as well now that we see (with our own eyes) the company has shamelessly reverted back to their sleazy tactics in pennyland. That's Christopher Moreau's way of concentrating on the fundamentals.
Yo shell! The email you're referring to is the same news release dump we all got. The bottom line is its underhanded. They are running the same penny world dilution play(s) as before. A so-called approval to uplist to NASDAQ has done nothing to raise capital at the least dilutive cost. Warrants are back in play on steroids. They're a total loser bunch spawned from Kulwant Malhi's hold on Nash Pharmaceuticals back in 2018. Rotten fruit doesn't fall far from the poisonous tree.
Failed leadership continues making shit up as they fumble and bumble along.
Pure Bait and Switch Bullshit
M$
I'm sure you are Carthnel. Especially with all the flipping over couch cushions cash ur making every time I post here as you lay claim.
You know who else is making money? Kulwant and Clan. They raked in 1 Million of that 1.5 Million cash burn last quarter (Q1).
You're talking about pennies versus real dollars buddy.
Hav @ it
M$
SLIMEBALL NEWS DUMP AFTER-HOURS
It's Christopher Moreau and former Miraculins leadership running the company. What else would you expect at this point?
Testimony from a poster at Yahoo
Does the Rockefeller quote hold true for BLOZF or has Cannabix reached a tipping point with it's long running testing testing and more testing narrative?
It's my best guess the bottom here runs much deeper than now. IMO, a cash on hand Market Cap would be more inline with a true valuation for the foreseeable future.
They burned through $1.5M last quarter (Q1).
Have @ it
M$
Call it taboo. Call it voodoo. Neither is what I do. I simply tell my truth. I'm no long-er searching for an exit. The answer is now crystal clear in my mind's eye.
The Exit: NASDAQ Uplist and Topline Data Readout. Whichever is the latter shall become my infinitely final days posting here. Whether or not I and/or assembled team continue following this stock's journey and other biotechs in a different format remains a work in progress.
Stay tuned Algernauts,
M$
Outro For Algernon's Inferno:
It's been hashed and re-hashished (smoked) a quintillion times now regarding the FACT Breathtec Biomedical (now Algernon) & Cannabix collaborated on the EGG ZAK same device technology. Same tech, same lab(s), same pot of money used to push the tech forward. What you see at Cannabix has Algernon's DNA within it. So what there was proclaimed competition with Breathtec Biomedical. There remains competition with Cannabix as well. Very serious competition. It hasn't stopped Cannabix from pumping the hell out of a narrative about testing this-that-other for 8 years and counting. Bottom line is shareholders of Algernon got duped when Christopher Moreau came in with a wrecking ball and did the opposite of what he claimed verbally and in writing. Shareholders knew it was a wrap with the FAIMS technology well before Moreau officially scrapped the FAIMS device. How did shareholders know? By someone's Due Diligence on this message board (can't recall who) in finding out Dr. Richard Yost (brainchild) had jumped ship and went to work for Owlstone Medical - a so-called competitor. Neither Christopher Moreau nor Dr. Yost felt the need to inform shareholders of Yost's departure. Yost just sailed off into the sunset across the Atlantic without a word of gratitude to shareholders. F*** YOST & University of Florida & Cannabix Technologies Inc. If you read GVX post regarding Cannabix it eludes to the fact simply having a device to PUMP a story can sustain a company for years on end. However, Moreau's track record of storytelling remains dismal at best. He even ran out of running the mouth runway at Miraculins with his failed device(s) leading to bankruptcy. Yeah, all that's old is always new at Algernon Pharmaceuticals Inc. Including Dr. Williams (brainchild) having once bailed out of Algernon Pharmaceuticals Inc.
One point that should be fully understood regarding Algernon's position on the FAIMS technology: The road to success was not as difficult as it remains for Cannabix. Algernon's stated goal for the FAIMS tech was simply having a portable device where other scientists would use the device to explore/detect whatever they wanted to chase down beyond controlled substances. Cannabix has the same device that will do the same thing. They simply have used vague language in their presentations to make it appear less obvious they ripped off shareholders at Algernon. I'm of the firm belief it was all part of a cooked up deal involving the reverse takeover of Breathtec Biomedical by Nash Pharmaceuticals whose #1 shareholder was of course Kulwant Malhi. There hasn't been a single thing at Algernon since the Breathtec days where King Cobra hasn't found a way to ROYALLY screw over shareholders at every turn of events. Which includes Moreau and Doc Williams shamelessly going to work for King Cobra at failed First Responders Technologies. Malhi retained power over the CEO of Algernon long enough to flip millions upon millions of shares of AGN/PF on behalf of another company and himself. It's immoral if not illegal and shareholders suffer to this day for the bullshit Moreau does on behalf of himself and others with power over him. Moreau is a puppet. 4+ years of Moreau's leadership and where does the company stand other than at the edge of another cliff?
OAN: Yeah shell. I don't know why there's no filed communications at CSE regarding NASDAQ. All I know is CSE is a trash ass rock bottom stock exchange. That's obvious considering how the "conflicts of interest" clauses filed by companies listed on the CSE somehow doesn't cross over into the criminal arena.
In regards to the long awaited IPF/CC data readout, I'm of the belief it is thoroughly baked into the rotten cake. Just like the failed COVID-19 study was explained at the very last minute by Moreau...it will take an overwhelming amount of positive data to move the needle. The IPF/CC study was not powered for stat sig. Algernon will need to tee up another Phase 2 study before having a chance at Phase 3. Another long drawn out study in Australia is Algernon's current plan. Surely not a speedy trial in the USA like Bellus Health conducted from start to data readout within 1 year. Can you imagine the type of fire sale dilution that will occur between now and then with three or four other Phase 1 studies needing cash if any move forward? Moreau will have the outstanding share count back to 100 million in no time flat like Usain Bolt. All the while smiling and telling shareholders about wanting to change their lives in a significant way. Break even on pre-split shares will likely require Algernon to have a Market Cap in the billions of dollars. Short of a miracle that's the plan I see unfolding here. Algernon's umpteen million previous claims of entering the clinical trial phase at Phase 2 has been completely blown out of the water. You think Moreau would land another CEO job somewhere else in pennyland? Perhaps, but it's no longer necessary. Performance be damned due to weak shareholders. Moreau has structured a long-term income and retirement plan for himself @ Algernon Pharmaceuticals Inc.
It's A Lifestyle!!!
Yours truly,
M$
algernonpharma.com
algernauts.com
From what I can tell, there isn't a new MDA filing since April 2022. Also, your MDA link is incorrect.
The burn rate from the quarter ending in February 2022 versus cash on hand points to the company being F L A T______B R O K E.
Peace,
M$
The so-called CEO is bent over a barrel (probably lovin' it) as shareholders fingers (digits) continue getting cut off (draining/diluting blood) to raise capital for a cash strapped company on the brink of bankruptcy. Moreau's past immoral acts have finally caught up with him at the worst time in the worst way for shareholders. It's obvious that his words and deeds have yet to carry the day in the eyes of would be newbie investors. It's a silly ass eight million dollar capital raise (in the grand scheme of things) and he's struggling to meet the mark/moment. Everything he touches becomes a long drawn out struggle. How anyone believes Christopher J. Moreau is a real CEO needs their head examined. I wouldn't put that guy in charge of a lemonade stand much less running a public company. My best guess is if long-winded Algernon Pharmaceuticals survives it will be shorted to no end. Sub $1 days are on the horizon. Hold onto your ass. The next cliff will be much steeper than the last.
https://algernonpharma.com/
M$
Correction: After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Billion shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
Full Stop
Having given the latest F-1/A another look, the Outstanding Shares including the giveaways will increase the outstanding to north of 5 Million Outstanding Shares not including the warrants. If the company survives through all the basement level Phase 1 studies in the pipeline, another massive dilution scheme will take place yet again to move any of them to Phase 2. From there, the question becomes whether or not any of those studies will be powered for stat sig or just another study to determine if they want to move to a real Phase 2 study powered for stat sig. The entire business model is set up for collosal and catastrophic dilution. Moreau will dilute the company back to 100 Million plus shares in no time flat. The pre reverse split shares will literally be worthless. As it would take a Billions upon Billions of dollars market cap to get close to break even. None of their plans are on your side and their timelines are set for them to retire at ripe old ages while draining the public of pennies with pathetic stories. These people have put on a master class of how penny world execs operate in the real world lowlife bowels of the stock market. I've yet to be proven wrong and the numbers don't lie.
Christopher Moreau's goal is to make a life changing difference for shareholders. Anybody remember that tripe spewing out of his mouth in one of those webcast stories?
Newsflash: Moreau wasn't really talking to you. He was talking to the people he loves cherishes and worships. Insiders and anyone else he enjoys getting bent over the rails of their yacht parked along the coastline anywhere in the world. A remote office location for the insiders...yeah I get. It's a lifestyle.
M$
Trouble Trouble and more Trouble
The latest dilution plan has now gone from - "This prospectus relates to an underwritten public offering of 1,931,922 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.348"
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm
To - "This prospectus relates to an underwritten public offering of 2,133,333 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.125."
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322014238/formf1a.htm
Trouble selling a 4 cents pre reverse split (100 to 1) stock story to family friends Cayman Islands ghost ship investors, etc etc.
It Remains Amateur Hour (+Days, Weeks, Months, Years) @ Algernon Pharmaceuticals Inc.
After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Million shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
The dilution moving forward will be at a clip that someone who can't even calculate 2 + 2 will understand. That's if the company ever moves forward >>>
M$
Umm...yeah.
www.algernauts.com
M$
Memorial Day: Remembering Our Fallen Soldiers
Open Question: Go to Page 3 of Algernon Pharmaceuticals - Financial Statements for quarter ended February 28, 2022:
https://webfiles.thecse.com/AlgernonFEB2822FS.pdf?AqxYNIv1.sQXRJQuDMoQZ7yyBewc9eZL
Do you see the type of money being spent on Marketing & Shareholder Communications?
Now look here:
https://www.godaddy.com/domainsearch/find?checkAvail=1&domainToCheck=algernonpharma.com
What I'm saying is the company should have secured this web address from the very beginning. It's the most logical web address for ease of use - less characters is better than more characters. Management should wise up. Someone at yahoo even got livid over it stating there should be legal actions involved. Yeah, that makes a lot of sense. Pay lawyers instead of securing something that can better enhance their overall exposure. Website/email etc etc etc... I'm no expert but I know "algernonpharma.com" looks better than algernonpharmaceuticals.com and the name itself AlgernonPharma versus Algernon Pharmaceuticals. If you go to Algernon's twitter page it says Algernon Pharmaceuticals@AlgernonPharma. It would seem logical that someone thought AlgernonPharma makes sense for Twitter - but not their corporate web address? They don't have to take heed but spending money on a relentless slew of Fly-By-Night web videos is hardly a comparison to rock solid domain name(s).
What the experts say:
https://www.networksolutions.com/blog/establish/domains/why-secure-more-than-one-domain-for-your-business-
Think Clearly:
https://expat-solution-coaching.com/wp-content/uploads/2019/01/its-just-business.jpg
Hav @ It
M$
Outro
The Outside Man Looking For The Inside Man
My best guess is delusion and dilution will be synonymous to the Algernon story for the foreseeable future. In Christopher Moreau's (CEO) case he takes the cake with Delusions of Grandeur.
As it all relates to this msg board...here we go AGAIN!
Yo tcm55, I get where you're coming from but unfortunately it doesn't mean jack shit as it relates to the COVID-19 study having been a complete flop.
Are you aware of the fact that Interleukin 6 (IL-6) was not...I repeat WAS NOT a Primary or Secondary Outcome (Endpoint) of the COVID-19 study.
https://clinicaltrials.gov/ct2/show/NCT04382924
My Commentary: What you have with Interleukin 6 (IL-6) is after the fact bullshit. If it meant anything of actual significance for the COVID study Moreau wouldn't have finally surrendered to his lame ass narrative about approaching the FDA to move to Phase 3.
Furthermore, Andre Uddin also would have pointed out any statistical significance to his clients that cling to his every word. Thus, it would appear that the only two people who believed in a chance in hell for COVID-19 at Phase 3 is you and Moreau. The overall market responded harshly and rightfully so to Topline data and the stock has never recovered since.
News Release - "Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19."
^Interleukin 6...Guess What...Nobody Cares.
________________
Article Regarding Andre Uddin: In an update to clients on Wednesday, Uddin moved AGN from a “Speculative Buy” to a “Hold,” saying investors should now be focusing on Algernon’s data for its idiopathic pulmonary fibrosis trial, due in the second half of 2021.
Ifenprodil missed the primary endpoint by showing no difference from the control group, while on all-cause mortality, the drug showed a very small non-significant improvement compared to the control group. On oxygenation, 100 per cent of patients with low blood oxygen on Ifenprodil returned to normal oxygen levels at Day 4 compared to Day 9 for patients in the control group, and on time in ICU, patients on the drug spent significantly less time in the ICU than those in the control group.
Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”
“Ifenprodil is in a Phase 2a trial in IPF/chronic cough where results are expected in H2 2021, and AGN’s DMT (a repurposed psychedelic compound) is expected to enter into a Phase 1 trial in stroke in H2 2021,” Uddin wrote. “Investors should re-focus their attention towards the IPF/cough data expected in H2 ’21.”
“Investors should note our AGN valuation is based on the IPF and chronic cough indications of ifenprodil – we are currently keeping our financial assumptions for the two indications intact in our model. We never assumed any revenues from ifenprodil’s COVID-19 indication,” he said.
Along with the new “Hold” rating, Uddin has cut his price target from $0.80 to $0.25, saying the drop is due to a decrease in assumed success rate for Ifenprodil. At the time of publication, the new target represented a projected one-year return of negative 15 per cent.
https://www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
________________
My Commentary:
Uddin's Hold rating of $0.25 is $0.20 USD (20 Cents per share). That's before the very harsh 100 to 1 reverse split. So Uddin's Hold rating would now represent a $20 USD share price at 1.68M Outstanding Shares. That's a Market Cap of $33.6M USD. Also, Uddin expected IPF/Chronic Cough data a year ago! Given the pending dilution and the crazy timeline to data there is no way Uddin still stands by that analysis. However, it appears that Algernon has cozied up to Uddin based on the Corporate Presentation having a banner with Andre Uddin as it's inhouse stock analyst. If anyone is getting word from Uddin about Algernon moving forward it likely would come in the same way the BioPub Dr. KSS looks out for his personal subscribers who pays him money for information. Algernon liked to wrap itself around people whose primary goal is to look out for everyone except common shareholders. Without an inside man you hold a shitty hand.
At the time of Uddin's analysis his projected 1 year return was negative 15 percent (15%).
To date, the return is in fact negative 78 percent (78%).
In reverse split adjustment terms since Uddin's analysis - the stock has dropped from $20 USD to $4.23 USD.
Pending dilution and the NASDAQ uplist will further wipe pre split shares off the map for the foreseeable future.
Ur On The Outside Looking In
As it relates to the Lockout in Australia...it speaks to the border. It does not speak to a Lock-down of it's residents like in China. Don't get the two twisted up in some cockamamie idea that their both one and the same. The bottom-line remains that Australia has a small population pool of potential clinical trial participants. That includes New Zealand where Algernon also remained stymied with dismal enrollment. Yet, the plan for Algernon is to go back to Australia for another slow rolled study of IPF and/or Chronic Cough. How wack is that?! V E R Y
Hav @ it
M$
TCM55
Just so you know...the FDA will approve of someone's grandma 's recipe for turkey gravy to conduct a study on how fat mice can get by licking it up.
Meanwhile, do you remember Christopher Moreau (CEO) telling the market back in Q4 how EXCITING it was going to be for Algernon Pharmaceuticals in 2022?
It would appear that dredging up old stories suggests one isn't very excited at all. It's gotta be killing Moreau to not be in front of a lens spinning and spewing more stories.
The following web address + email address would be money well spent, but like everything else Moreau does, it'll likely be something management/shareholders will learn the hard way:
https://algernonpharma.com/
After all, all the so-called marketing has been Algernon's biggest quarterly expense. Anybody think they've gotten their monies worth to date?
Expect more of the same...
M$
P.S Anyone seen or heard from the BioPub Boys lately? I'm not a subscriber so I'm curious to know if they're still receiving private updates by the CEO & Company? Maybe it doesn't matter since Dr. KSS remains an insiders advisor (conflict of interest) @ Algernon Pharmaceuticals Inc.
We Know. Carry On. EOM M$
I'm living rent free in that empty space @ BLOZF
M$
Nice! Be Well. EOM M$
mindmed.co/addapt/
COVID Breathalyzer
UNT built a breathalyzer that detects COVID. A Frisco company just got FDA approval to put it to work.
How does the device work, exactly?
Verbeck explained that the technology mimics the carbon filter in your refrigerator.
“Carbon is very good at capturing organics and getting them out of your water,” Verbeck said. “So, think of it as exactly the same sort of process. We’ve sort of a carbon substrate — and it is a carbon substrate, but it’s got some extra things in it — that turns to the chemistry that you’re interested in looking at. So, when you’re in a disease state like COVID, your respiratory cells die. They go apoptotic. Which is just a fancy word for cell death.”
When those cells die, Verbeck said, small organic compounds are released that are unique to COVID.
“Those organic molecules are the ones that we’re capturing, and re-releasing back into the instruments,” Verbeck said. “So, that’s called pre-concentrating. So, we just take it, we concentrate onto the substrate like a carbon filter and then we evacuate it, heat it up and off comes the volatile organic compounds that we’re interested in identifying. So, it takes a small amount of air to detect these organic compounds.”
https://dentonrc.com/business/unt-built-a-breathalyzer-that-detects-covid-a-frisco-company-just-got-fda-approval-to/article_a569a515-777c-5ee9-8e40-8fa052e535e3.html
Once upon a time...there was a FAIMS device. A device aimed at detecting diseases or anything else Scientists/Lab Rats wanted to chase after. Then along came Christopher Moreau and the rest of the FAIMS story is history.
The End
M$
Postscript
It's companies and innovators like that where Cannabix is in serious trouble. The timeline for Cannabix to complete anything is a very troubling situation for common shareholders to say the least. Beyond that, Christopher Moreau @ Algernon Pharmaceuticals (formerly Breathtec Biomedical) handed Cannabix complete rein over the FAIMS technology to pursue whatever without getting one dime/one share out of Cannabix for it's long-standing monetary collaboration to push the FAIMS technology forward. It says a lot about the character of people running both companies. One ruthless and selfish and the other pure cowardice and uncaring.
Of note: Raj Attariwala remains the last true thread between both companies throughout it all as Board of Director of both companies. Notwithstanding Kulwant Malhi is/was the Puppet Master of all of them.
Have @ it
COVID Breathalyzer
UNT built a breathalyzer that detects COVID. A Frisco company just got FDA approval to put it to work.
How does the device work, exactly?
Verbeck explained that the technology mimics the carbon filter in your refrigerator.
“Carbon is very good at capturing organics and getting them out of your water,” Verbeck said. “So, think of it as exactly the same sort of process. We’ve sort of a carbon substrate — and it is a carbon substrate, but it’s got some extra things in it — that turns to the chemistry that you’re interested in looking at. So, when you’re in a disease state like COVID, your respiratory cells die. They go apoptotic. Which is just a fancy word for cell death.”
When those cells die, Verbeck said, small organic compounds are released that are unique to COVID.
“Those organic molecules are the ones that we’re capturing, and re-releasing back into the instruments,” Verbeck said. “So, that’s called pre-concentrating. So, we just take it, we concentrate onto the substrate like a carbon filter and then we evacuate it, heat it up and off comes the volatile organic compounds that we’re interested in identifying. So, it takes a small amount of air to detect these organic compounds.”
https://dentonrc.com/business/unt-built-a-breathalyzer-that-detects-covid-a-frisco-company-just-got-fda-approval-to/article_a569a515-777c-5ee9-8e40-8fa052e535e3.html
Once upon a time...there was a FAIMS device. A device aimed at detecting diseases or anything else Scientists/Lab Rats wanted to chase after. Then along came Christopher Moreau and the rest of FAIMS story is history.
The End
M$
Fake A$$ Wall @ 40 Cents that keeps popping up is the only thing keeping it from dumping to 20 Cents. Surely King Cobra and the Cayman Islands Crew are hanging on for dear life.
Once Cannabix goes bust...the only thing left for King Cobra in pennyland will be Coloured Ties Capital - formerly Growmax Resources.
Then again...he can always change the name of Cannabix and start yet another dumpster fire (in a long line) with the leftover rubble.
TGIF
M$
Correct. All that crap about congress and bills is a BS waste of time/read. Simply look at the Cannabis sector. Ranting to no end year after year about introducing bills. Hasn't stopped the cream of the crop from prospering. Same will happen in the psych sector. However, Big Pharma will take over and the skies will open up for whomever has successful Phase 3 data. Tinfoil hat politicians are not running anything with introducing bill after bill written on toilet paper. The success or failure of any psych sector stick is Data Driven - Period. Everything else is pure entertainment.
M$
You actually believe I bare some responsibility for "suppressing" the share price? LMAO. Just wait until the truly professional shorts get ahold of "AGNP" in a Bear Market no less. Certainly you know I have absolutely nothing to do with Christopher Moreau driving the bus over the cliff along with a 20 participant data readout still awaiting closure after 2 years.
Final Data will likely extend the unBEARable drama another 6 months. 2.5 years to complete a 6 months or less "study" had it been conducted in North America. Bellus Health had more than 10 times the participants and got it done in less than 1 year. It's no pure comparison by any stretch of the imagination but that won't stop Mush Mouth Moreau from trying to make it so.
Any thought of what the share price might be now had Algernon gotten positive Chronic Cough data back in 2020 or Q1 2022? Data that could have gone head up with Bellus Health. My best guess is AGNPF would be north of $1 without having orchestrated a punishing 100:1 reverse split. The momentum and everything else got sucked straight into a black hole in Australia.
Did I mention the Minds of Management is going back to that same lame ass Phase 2 (a? b? b3?) "tax write-off' scenario in Australia for it's next Phase 2 (a? b? b3?) IPF/Chronic Cough study? Incredible how they've traveled full circle to expose themselves (the emperors has no clothes) as true dilution machine whores.
Whores : to pursue an unworthy desire.
In any event, 3.5 years into the Black Hole Annals of Algernon Pharmaceuticals (The Shit Stinks)...
I've shaved many shares along the way since holding well north of a million shares of this Shit Show Stock. Whether or not I've made any money along the way is irrelevant. What's relevant is Facts over Fiction - Reality over Virtual Reality - Activism over Appeasement. I have not changed since Day 1 (A1). It remains my opinion that your analogy of where things stand is kooky at best.
To anyone who finds themselves falling down the rabbit hole of stories told by the CEO... Beware the Black Hole.
M$
Down the rabbit hole stuff
Have @ it
I'm active elsewhere
M$
No worries. The tcm here couldn't possibly be the same tcm there. Got it! However, both tcm's have come up with a random number of 10M Outstanding Shares (OS) issued - from doubling the current OS - to the pending OS (3.5M) - to instead QUINTUPLING (10M) the current OS - as some sort of loyalty reward for shareholders. I think it's the kookiest thing I've read yet about the Nasdaq uplist - to include bonuses for management (What the fuuu)?
Sir, I applied simple math in my previous post as one overwhelmingly EZ to understand example of why that idea would help absolutely no one. I will leave it to others to come to their own conclusions. Furthermore, I believe everyone who reads this msg board already knows how to navigate their way to other Algernon message boards to read and/or opine. You make it seem as if the internet itself is a newly discovered phenomenon.
Just to add further clarity here as if it's necessary:
tcm - "...will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds."
What I gather is YOU STILL do not understand that the IPO is etched in stone to the point the Market Cap is irrelevant to raising further capital in the immediate future. The 8.4M USD is the number they will come away with (actually it's 7.4M USD).
Now go back and look at the SEC F1/A filing to see how much of that money is to be allocated for Chronic Cough. It shows 500k is going towards ANOTHER Phase 2 trial in Australia. Not only that, it's not a standalone Chronic Cough study. It's including IFP which Moron Moreau himself said is a bad idea.
Yet...here they are again doing the same thing over again in a country that he knows will slow roll enrollment. Algernon Pharmaceuticals is being ran by natural born losers.
Expect another capital raise in 2023 if any of the Phase 1's come away with any data subject to further pursuit. Given "safety" is the only hurdle at Phase 1, surely you can expect "AGNP" will soon become a shorts Dream Dilution Machine on steroids for years to come.
Someone ask Beer Buddy when does he expect a Phase 2 Chronic Cough study to start in Australia - and when does he expect it to end. Then add at least 1 year to whatever answer spews out of his mouth.
Note that Bellus Health ran their USA standalone Phase 2 Chronic Cough clinical trial in less than one year from beginning to Final Data Readout. Remember that everytime Moreau mentions them as a pure comparison.
Mark this post.
M$
Re: Discussion from AGNPF Yahoo msg board
@tcmoiba That's absolutely nuts! You are advocating for yet more dilution where $30 is already the break even point for pre split shares. Absolutely bonkers idea. The stock will already be luck to trade above $3 once uplisted. Do simple math. They are selling more than half the company for $8 million. That means the current market cap of $6 million to $7 millions is what the market believes the company is worth. Adding $8 million to run clinical trials doesn't increase the overall value at Phase 1. So here's more simple math ... Take the current market cap of 6 million and add the 8 million capital raise. That puts you at 14 million market cap. Divide the 14 million by 3.5 million shares outstanding. That leaves you with a share price of $4 USD. Now go look at XRTX where they recently uplisted and Algernon's CEO compares Algernon's uplist to. XRTX is trading at sub $2 per share at less than 20 million market cap and they are already conducting clinical trials. That's where Algernon is headed on the Nasdaq. This stock is prime for getting the #$%$ shorted out if it like never before in penny world. Live and Learn the Hard Way.
__________________________
IMO, Christopher Moreau can remain on his webcast crusade but it's not going to do a damn thing for the share price at Phase 1. Surely, he will be in a - forget about the past - mode and barrel ahead head first towards another cliff.
The best thing they could do with that 8 million is doend it all on a standalone Chronic Cough clinical trial powered for statistical significance and conducted in North America That is Algernon's best and likely OBLY true shot at getting shareholders back to even @ $30 per share. Will that happen...of course not. They are too busy diluting the company for pie in the sky BS and flavor of the month angles. Before it was covid...now it's psychedelics. Once they drive the bus over the next cliff they will be onto whatever else becomes a hot topic. Meanwhile, Bellus Health is rolling up their sleeves and doing real world pharma deals not virtual reality management shit - phoning it in.
M$
Do you believe that post is relevant or it's just plastered at the top for some day in the coming years to say I told you so?
M$
You have a poor memory AND your analogy is completely wack. Without providing you a full understanding of the situation Cannabix began with a spit contraption from overseas. That spit contraption had already previously been debunked as garbage by none other than Dr. Marilyn Heustis BEFORE Cannabix began peddling a narrative about it being the next best thing since sliced bread. From there it's been nothing but a long and winding road from one iteration to another about testing this or that. What you refuse to wrap your brain around is Cannabix has never had its device in the hands of cops. It's never gone through any rigorous testing such as hound labs did with cops from across the country for testing prior to completing their device - peer reviewed. Cannabix has talked about running FDA clinical trials and court approvals this and that. It's all smoke and mirrors and those steps will take years if they ever get beyond the prototype phase. Which phase are they on now? Going on Phase 5 and/or scrapping that and turning toward their latest so-called backup technology - The prototype Contactless Alcohol Breathalyzer (“CAB”). Yeah, another prototype. That'll do the trick! You simply don't understand the facts as written in plain English and plain sight. Enough lessons for today.
Someone please call me a CAB
M$
After 8 years of you following the story surely you would think that Cannabix is leading anything. Yeah, just forget about Hound Labs and Vox. Do you see the size of that breathalyzer their working to completion? My best guess is they will enter the market well before Cannabix ever/if ever they get to a real world contraption. Surely, I dought it. Thanks for another LOL moment.
Meanwhile, have at your interpretations.
M$
Our most important goal remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's capability of building easy-to-use portable testing equipment. We intend to use the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk", to develop a series of devices and tests that could be used at roadside, emergency rooms and in workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse. The first test we intend to offer is the SpinDx device with disks for delta-9-THC detection from an oral fluid sample collected from a test subject. Then we intend to offer a device based on our recently updated LX9 breathalyzer to collect a sample for analysis from breath, which coupled with the SpinDx device will be our marijuana breathalyzer system. We have improved the detection sensitivity for delta-9-THC as well as the test speed and robustness of the device. We are continuing to work on developing this system into a device that can be used for roadside testing, as well as other contexts requiring fast response. Additional personnel and new equipment resources have been committed to finalizing the development of the first products of the SpinDx technology platform.
News Release @Lifeloc
LX9 Breathalyzer
Tic Toc @Cannabix
OAN: Yeah dude, that answers the question with a barrage of silly questions. ROTFLMAO as usual.
M$